Absci Corporation (ABSI) Q3 2025 Earnings Call Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2025
0mins
Source: SeekingAlpha
Revenue $400,000 for the third quarter, with no year-over-year change mentioned.
Research and Development Expenses $19.2 million for the three months ended September 30, 2025, compared to $18 million for the prior year period, representing an increase. The increase was primarily driven by advancement of Absci's internal programs, including direct costs associated with external, preclinical, and clinical development.
Selling, General, and Administrative Expenses $8.4 million for the three months ended September 30, 2025, compared to $9.3 million for the prior year period, representing a decrease. The decrease was primarily due to a decrease in personnel-related expenses.
Cash, Cash Equivalents, and Marketable Securities $152.5 million as of September 30, 2025, compared to $117.5 million as of June 30, 2025, showing an increase. The increase was attributed to the company's financial management and operations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABSI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABSI
Wall Street analysts forecast ABSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABSI is 7.66 USD with a low forecast of 4.32 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.940
Low
4.32
Averages
7.66
High
10.00
Current: 2.940
Low
4.32
Averages
7.66
High
10.00
About ABSI
Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ARK Genomic Revolution ETF Falls 2.5%, Personalis Drops 9.8%
- ETF Underperformance: The ARK Genomic Revolution ETF fell approximately 2.5% during Thursday afternoon trading, indicating a decline in market confidence in the sector, which may affect future capital inflows.
- Stock Weakness: Within the ETF, shares of Personalis dropped about 9.8%, while Absci fell approximately 8.6%, suggesting that these companies' performances failed to meet market expectations, potentially leading investors to reassess their investment value.
- Market Sentiment Fluctuation: The overall poor performance of the ETF may trigger investor concerns regarding the genomics sector, which could impact the financing capabilities and market positioning of related companies.
- Uncertain Industry Outlook: As competition intensifies in the genomics industry, the decline of the ARK ETF may signal a decrease in investor confidence regarding the sector's future growth potential, thereby affecting the overall strategic development of the industry.
Continue Reading
Absci to Present AI Drug Innovations at 44th J.P. Morgan Healthcare Conference
- Conference Participation: Absci Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 3:45 PM PT, showcasing its latest advancements in AI-driven drug discovery, which is expected to attract significant investor and industry interest.
- Technological Innovation: The company's Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, significantly accelerating the design of innovative therapeutics to address complex therapeutic targets, thereby driving rapid advancements in the biopharmaceutical industry.
- Product Pipeline: Absci is advancing AI-designed therapeutics, including ABS-201™, which is recognized as a groundbreaking innovation for treating androgenetic alopecia and has the potential to become a “best-in-class” therapeutic for endometriosis, addressing significant unmet medical needs in the market.
- Global Presence: With its headquarters in Vancouver, WA, an AI research lab in New York City, and an innovation center in Switzerland, Absci demonstrates a global R&D strategy aimed at accelerating drug development through international collaborations.
Continue Reading